Streetbeat News

OTSKY

Otsuka Holdings Co.,Ltd.

Industry

Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)

Open

25.38

Mkt cap

27B

Volume

8.2K

High

25.43

P/E Ratio

28.24

52-wk high

32.41

Low

25.15

Div yield

0.02

52-wk low

17.10

Otsuka Holdings reported a significant increase in Q3 earnings and sales, with EPS rising 36.84% to $0.52 and sales increasing 13.43% to $4.17 billion compared to the same period last year.

Portfolio Pulse from Benzinga Newsdesk

October 31, 2024 | 11:15 am

IGC Pharma Inc (NYSE:IGC) announced positive interim Phase 2 trial results for IGC-AD1, showing significant reduction in Alzheimer's Disease agitation compared to placebo. The trial used the Cohen Mansfield Agitation Inventory for assessment, with notable improvements as early as week two. In contrast, Otsuka Holding Co Ltd's (OTC:OTSKY) (OTC:OTSKF) Rexulti received FDA approval with less pronounced effects in a similar context. IGC's stock dropped 13.80% to $0.33 following the announcement.

Portfolio Pulse from Vandana Singh

March 20, 2024 | 5:21 pm

Medtronic's Symplicity Spyral RDN System, a device for treating high blood pressure, has faced a regulatory setback as the FDA Circulatory System Devices Panel voted against its approval, citing that the risks do not outweigh the benefits. Meanwhile, the same panel backed a similar device by Recor Medical and its parent company, Otsuka Medical Devices. Medtronic's shares fell 1.24% in premarket trading following the news.

Portfolio Pulse from Vandana Singh

August 24, 2023 | 12:45 pm

The FDA's Circulatory Systems Devices Panel has backed Recor Medical Inc and its parent company, Otsuka Medical Devices Co Ltd's (OTC:OTSKF) (OTC:OTSKY) hypertension treatment device, the Paradise Ultrasound RDN system. The panel voted unanimously in favor of the device's safety and majority in favor of its efficacy. If approved by the FDA, the device would be the first FDA-approved renal denervation device in the U.S. intended to reduce blood pressure in patients with uncontrolled hypertension.

Portfolio Pulse from Vandana Singh

August 23, 2023 | 1:34 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.